Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Delitzsch – page 36

1 023 clinical trials in Delitzsch, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Delitzsch at a glance
1 023
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 023 trials in Delitzsch

Open in trial search

Colitis ulcerative+1

Not yet recruiting

Study of ABBV-701 and Risankizumab Combination vs Monotherapy in Adults with Moderately to Severely Active Crohn’s Disease or Ulcerative Colitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Efficacy of efgartigimod alfa as first‑line add‑on to IV methylprednisolone for moderate‑to‑severe attacks in patients with demyelinating diseases

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Medizinische Hochschule Hannover

Colitis ulcerative+1

Not yet recruiting

Study of risankizumab plus anti‑α4β7 integrin antibody versus each alone in adults with moderately to severely active Crohn’s disease or ulcerative colitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Type 2 diabetes mellitus

Not yet recruiting

Phase 3 Study of Maridebart Cafraglutide versus Semaglutide as Add‑on to Metformin (± SGLT‑2 Inhibitor) in Adults with Type 2 Diabetes Not Controlled by Metformin

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Amgen Inc.

Endometrial cancer

Not yet recruiting

Maintenance Treatment Study of gsk5733584 with dostarlimab or pembrolizumab in patients with mismatch repair proficient advanced or recurrent endometrial cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Randomized phase III study of AAA817 plus an androgen receptor pathway inhibitor in adult men with PSMA‑positive metastatic castration‑resistant prostate cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Novartis Pharma AG

Bronchitis+1

Not yet recruiting

Study of galvokimig versus placebo to assess safety and effectiveness in adults with moderate‑to‑severe chronic obstructive pulmonary disease with chronic bronchitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Galvokimig
  • Sponsor:UCB Biopharma

Lichen planus

Not yet recruiting

Efficacy and safety of GIA632 versus placebo in adults with moderate to severe cutaneous lichen planus

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:GIA632
  • Sponsor:Novartis Pharma AG

Phase 2 Study of Weekly Ficerafusp Alfa + Pembrolizumab vs Alternative Dosing in First‑Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ficerafusp alfa
  • Sponsor:Bicara Therapeutics Inc.

Multiple sclerosis

Not yet recruiting

Long‑Term Safety and Tolerability of Frexalimab Drug Combination in Adults with Multiple Sclerosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Colestyramine
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Anaemia+1

Not yet recruiting

Study of Elritercept (TAK‑226) with Ruxolitinib vs Placebo in Patients with Myelofibrosis and Anemia on Ruxolitinib Therapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Elritercept
  • Sponsor:Takeda Development Center Americas Inc.

Safety and efficacy of efimosfermin alfa versus placebo in adults with compensated cirrhosis (stage F4) due to MASH

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Delitzsch

What the registry says about research in the country

01 Respiratory Diseases

Groundbreaking research focusing on severe asthma and its various manifestations, including studies evaluating new therapeutic approaches for patients with inadequate response to standard treatments.

  • Asthma exacerbation prevention
  • Eosinophilic asthma management
  • Rescue medication optimization

Multiple trials exploring innovative treatment combinations and delivery systems to improve patient outcomes.

02 Pulmonary Medicine

Comprehensive studies addressing Chronic Obstructive Pulmonary Disease, investigating advanced therapeutic options through triple therapy combinations.

  • COPD exacerbation reduction
  • Triple therapy enhancement
  • Chronic bronchitis treatment

Research aimed at improving long-term management and quality of life for COPD patients.

03 Infectious Diseases

Innovative vaccine development research targeting Cytomegalovirus (CMV) infection, with a focus on prevention strategies in high-risk populations.

  • CMV infection prevention
  • Vaccine immunogenicity
  • Primary infection protection

Trials evaluating novel mRNA-based vaccines to prevent primary CMV infection in seronegative individuals.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.